11.47
-0.09(-0.78%)
Currency In USD
| Previous Close | 11.56 |
| Open | 11.62 |
| Day High | 11.71 |
| Day Low | 11.25 |
| 52-Week High | 29.56 |
| 52-Week Low | 8.18 |
| Volume | 525,524 |
| Average Volume | 985,988 |
| Market Cap | 874.42M |
| PE | -4.11 |
| EPS | -2.79 |
| Moving Average 50 Days | 12.92 |
| Moving Average 200 Days | 19.88 |
| Change | -0.09 |
If you invested $1000 in Nurix Therapeutics, Inc. (NRIX) since IPO date, it would be worth $603.37 as of April 29, 2025 at a share price of $11.47. Whereas If you bought $1000 worth of Nurix Therapeutics, Inc. (NRIX) shares 3 years ago, it would be worth $1,036.13 as of April 29, 2025 at a share price of $11.47.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs
GlobeNewswire Inc.
11 hours ago
Nurix’s DEL-AI platform uses a first-in-class DEL Foundation Model trained on the Company’s proprietary DNA encoded library data Nurix’s DEL Foundation Model can accurately predict novel binders to therapeutically relevant targets, including many tar
Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets
GlobeNewswire Inc.
Apr 25, 2025 5:00 PM GMT
Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour BRAF degrader demonstrates broad activity across all three BRAF mutation classes Aurora A kin
Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions
GlobeNewswire Inc.
Apr 17, 2025 11:00 AM GMT
Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical applications across multiple blockbuster markets in i